Current drug delivery最新文献

{"title":"Mechanistic and Phytochemical Basis of Shexiang Xintongning Against Atherosclerosis: Insights from Network Pharmacology and Molecular Docking.","authors":"Mengyuan Wang, Guiyun Cao, Xiao Qiu, Rui Yang, Yu Liu, Lingqun Yu, Liyue Ren, Danyang Wang, Chao Li, Wenqing Yang, Zhaoqing Meng, Yunlun Li, Ying Yang","doi":"10.2174/0115672018404138251206210548","DOIUrl":"https://doi.org/10.2174/0115672018404138251206210548","url":null,"abstract":"<p><strong>Introduction: </strong>Shexiang Xintongning (SXN) is a Chinese medicinal compound used to treat cardiovascular diseases and has been formulated into a commercial tablet. Based on Traditional Chinese Medicine (TCM) theory, SXN has anti-atherosclerotic effects. Despite its clinical application, the mechanism of action of SXN remains poorly understood. This research seeks to clarify the molecular pathways and active constituents through which SXN combats atherosclerosis.</p><p><strong>Methods: </strong>In this study, network pharmacology was used to predict potential targets and biological processes involved in SXN's treatment of atherosclerosis (AS). AS was induced in <i>ApoE⁻/⁻</i> mice by feeding them a high-fat diet (HFD). The anti-atherosclerosis effects of SXN were observed in the aorta, aortic root, and serum. Based on the screening pathways and targets, experimental analyses were conducted to elucidate the mechanisms underlying its pharmacological action.</p><p><strong>Results: </strong>The chemical constituents of SXN were identified using UPLC/MS-MS analysis. The main components, including Muscone, Jasmone, Tetramethylpyrazine, Ferulic acid, trans-Cinnamic acid, and Senkyunolide H, were identified. Network pharmacology analysis revealed that the antiatherosclerotic effects of SXN were closely associated with the HIF-1 signaling pathway and the key factor HIF-1α. SXN significantly reduced atherosclerotic plaque formation, improved lipid profiles, suppressed inflammation, and alleviated oxidative stress in a dose-dependent manner. Mechanistically, SXN downregulated HIF-1α/HIF-2α while upregulating GPX4 and SLC7A11, indicating inhibition of ferroptosis.</p><p><strong>Discussion: </strong>These findings suggest that SXN exerts anti-atherosclerotic effects mainly by modulating the HIF-1 signaling pathway, improving lipid metabolism, attenuating inflammation and oxidative stress, and inhibiting ferroptosis, thereby providing mechanistic support for its traditional use in cardiovascular disease.</p><p><strong>Conclusion: </strong>SXN demonstrates significant anti-atherosclerotic efficacy by targeting the HIF- 1α/SLC7A11/GPX4 signaling axis, thereby elucidating novel mechanistic paradigms underlying cardiovascular therapeutic applications of Traditional Chinese Medicine and establishing ferroptosis as a critical molecular target for atherosclerotic disease intervention.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148379066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimization of Andrographolide Nanocrystal-loaded Liposomes by Box-Behnken Design and its <i>In vitro</i> and <i>In vivo</i> Evaluation.","authors":"Liangxing Tu, Siying Wang, Hansong Wu, Zijian Zou, Banghuai Xing, Lingyu Yang, Zhiyang Lu, Meng Cheng","doi":"10.2174/0115672018424105260129234917","DOIUrl":"https://doi.org/10.2174/0115672018424105260129234917","url":null,"abstract":"<p><strong>Introduction: </strong>The optimum process for andrographolide nanocrystal-loaded liposomes was optimized using Box-Behnken design, and its in vitro and in vivo evaluation was subsequently studied.</p><p><strong>Methods: </strong>Scanning electron microscopy, transmission electron microscopy, X-ray powder diffraction, and differential scanning calorimetry were used to study the physical and chemical properties. Short-term stability was assessed by measuring changes in particle size and PDI. The in vitro release behavior of andrographolide nanocrystals, andrographolide liposomes, and andrographolide nanocrystal- loaded liposomes in pure water and PBS buffer was studied by the dialysis bag method. The pharmacokinetic properties of andrographolide formulations in vivo were explored when using male Sprague-Dawley rats.</p><p><strong>Results: </strong>Encapsulation within liposomes, regardless of the initial drug form, effectively sustained the drug, with Slow release of 80 % in PBS (p<0.05). Andrographolide nanocrystal-loaded liposomes had good short-term stability. Additionally, the pharmacokinetic behavior showed that, excluding the higher Cmax of andrographolide liposomes and andrographolide nanocrystal-loaded liposomes, the pharmacokinetic parameters were similar (p<0.05). These hardly improve the pharmacokinetic behaviors by the intravenous route, and the potential mechanisms for the widely reported higher therapeutic efficacy of these technologies may be enhanced target efficacy or cellular uptake.</p><p><strong>Discussion: </strong>This study conducted in vitro and in vivo performance tests on liposomes loaded with nanocrystals, and explored the performance of this preparation from various perspectives.</p><p><strong>Conclusion: </strong>This nanocrystal-loaded liposomes display great potential for the therapeutic mechanisms of nanoformulations, and helps researchers to better design and understand the therapeutic mechanisms of nanoformulations.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148364719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Design and Optimization of Beta-Caryophyllene Nanoemulgel for Enhanced Antihyperlipidemic Activity: A Response Surface Approach.","authors":"Aarti V Udmale, Bhushan R Rane, Dinesh S Mutkule, Ashish S Jain","doi":"10.2174/0115672018423533260121055224","DOIUrl":"https://doi.org/10.2174/0115672018423533260121055224","url":null,"abstract":"<p><strong>Introduction: </strong>After COVID-19, there has been a significant rise in cardiovascular complications, including an increased risk of myocardial infarction, primarily associated with elevated lipid concentrations in the bloodstream. β-caryophyllene (β-CP), a naturally occurring compound with a bicyclic sesquiterpene structure found in various plants and essential oils, has demonstrated inhibitory activity against hyperlipidemia. One of the most inventive solutions for problems with weak absorption and limited solubility is nanoemulsion.</p><p><strong>Methods: </strong>In this study, β-CP nanoemulsion was prepared by a high-energy method followed by high-pressure homogenization (Panda Plus 2000) using Tween 80 and PEG 400 as surfactant and cosurfactant, respectively. The process was optimized using the Box-Behnken design, and the optimized nanoemulsion was incorporated into an in situ gel prepared by the cold method with poloxamer 407.</p><p><strong>Results: </strong>Various parameters of the improved nanoemulsion were evaluated, revealing an average particle size (61.77 nm), Zeta potential (-28.3 mV), and PDI (0.238). It enhanced solubility up to fivefold, making it acceptable for absorption into the systemic circulation via intranasal delivery. The improved in situ gel had good viscosity, spreadability, gelation, and mucoadhesive strength for ionic contact with the nasal mucosa. The in vitro release study showed that the optimized in situ gel achieved the highest drug release of 98.71% within 12 hours.</p><p><strong>Discussion: </strong>The improved solubility and sustained release were the result of the combined effect of nanoemulsion encapsulation and thermosensitive gelation. This dual system increased nasal residence time, enhanced absorption, and reduced side effects. Optimization using the Box-Behnken design ensured a stable and reproducible formulation.</p><p><strong>Conclusion: </strong>The findings suggest that an in situ nasal nanogel could be the most efficient approach for delivering β-cp into the systemic circulation for the treatment of hyperlipidemia.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148364667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Assessment of Rutin/Betamethasone-Loaded PAN-PVP Nanofibers for Wound Healing Applications.","authors":"Badriyah Shadid Alotaibi, Azka Sana, Han Cheng, Haya Yasin, Xianju Huang, Sana Rafique, Abida Kalsoom Khan, Munaza Ijaz, Ghulam Murtaza","doi":"10.2174/0115672018443891260117203100","DOIUrl":"https://doi.org/10.2174/0115672018443891260117203100","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to fabricate dual drug-loaded electrospun nanofibers composed of polyacrylonitrile (PAN) and polyvinylpyrrolidone (PVP) incorporating betamethasone dipropionate and rutin hydrate for improved wound healing.</p><p><strong>Methods: </strong>The nanofibers were characterized by various approaches, including SEM, FTIR, TGA, and XRD.</p><p><strong>Results: </strong>SEM images confirmed the formation of nanofibers with beaded morphology due to low solution viscosity. FTIR confirmed the presence of all components, while TGA indicated improved thermal stability upon drug loading. Franz-cell diffusion studies showed sustained drug release, and antibacterial assessments demonstrated effective inhibition of Staphylococcus aureus and Escherichia coli. In vivo, the drug-loaded nanofibers significantly accelerated wound contraction within 17 days. Histopathological evaluation (H&E staining) confirmed enhanced re-epithelialization and collagen organization compared to the marketed formulation.</p><p><strong>Discussion: </strong>The combined anti-inflammatory and antioxidant effects of betamethasone and rutin, delivered through a PAN-PVP fibrous matrix, contributed to rapid tissue repair, reduced inflammation, and effective microbial control. The sustained release behavior and favorable physicochemical properties underscore the suitability of the PAN-PVP system for multifunctional wound dressings. These findings highlight the potential translational value of dual-drug electrospun nanofibers as an advanced therapeutic option for managing complex wounds.</p><p><strong>Conclusion: </strong>These findings demonstrate the potential of PAN-PVP nanofibers as a wound dressing platform for localized transdermal delivery.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148310972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"QbD-Driven Rational Design of Vancomycin-Loaded Nanocubosome <i>In situ</i> Ocular Gels: Augmenting Precorneal Retention and Improving Anti-MRSA Keratitis Treatment.","authors":"Anvi Rathod, Priya Patel, Nirav Patel","doi":"10.2174/0115672018437230260529100808","DOIUrl":"https://doi.org/10.2174/0115672018437230260529100808","url":null,"abstract":"<p><strong>Introduction: </strong>Vancomycin hydrochloride (VAN) is the treatment of choice for methicillin- resistant Staphylococcus aureus (MRSA) keratitis, but poor corneal penetration, epithelial toxicity, and the need for frequent dosing highlight the need for advanced formulations. This study aimed to develop a VAN-loaded nanocubosomal in situ ophthalmic gel to enhance corneal bioavailability and residence time.</p><p><strong>Methods: </strong>VAN-loaded nanocubosomes (VAN-NCs) were prepared using a melt-dispersion emulsification technique based on Quality by Design (QbD) principles. The optimized nanocubosomes were incorporated into a pH-responsive in situ gel containing Carbopol 934 and HPMC E3.</p><p><strong>Results: </strong>The optimized formulation VAN-NCs exhibited a mean particle size of 100.8 nm, low PDI (0.15), high encapsulation efficiency (91.9%), and zeta potential of -20.4 mV. Glyceryl monooleate concentration, Poloxamer 407 level, and sonication time were identified as critical factors, achieving a desirability of 0.975. The in situ gel showed rapid pH-triggered gelation, sustained vancomycin release (~90% over 24 h; n = 0.82), and significantly higher ex vivo corneal permeation compared with free VAN gel. Stability studies confirmed >95% drug content over 30 days.</p><p><strong>Discussion: </strong>The optimized nanocubosomal in situ gel improved vancomycin ocular delivery by enhancing corneal permeation and sustaining drug release. The QbD-established design space confirmed formulation robustness and suitability of GMO-Poloxamer nanocubosomes for controlled ophthalmic antibiotic delivery.</p><p><strong>Conclusion: </strong>The VAN-NCs in situ gel demonstrated controlled drug release, enhanced corneal permeation, and good physicochemical stability. These results support its potential as an improved ocular delivery system for bacterial keratitis, warranting further in vivo evaluation.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148261122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Curcumin-based Nanotherapeutics to Combat Neurodegenerative Disease: Drug Delivery Strategies and Therapeutic Potential.","authors":"Yachana Mishra, Vijay Mishra","doi":"10.2174/0115672018480691260520045205","DOIUrl":"https://doi.org/10.2174/0115672018480691260520045205","url":null,"abstract":"<p><p>Curcumin (CUR) has been used as a medicine, colouring agent, and flavouring agent for thousands of years. Polyphenolic active constituents of turmeric show antimicrobial, anticancer, antioxidant, anti-inflammatory, astringent, and other valuable properties. Numerous studies on animals have demonstrated that CUR is safe, with no harmful effects on the kidney and liver, even at higher doses. This review article aims to gather information about the properties and the use of active constituents of CUR in nanotechnology-based treatment strategies for neurodegenerative diseases (NDs). From scientific articles published in different scientific platforms, including PubMed, Scopus, Web of Science, and Google Scholar, potentially relevant literature was compiled to update on CUR and innovative nanocarrier-based approaches for the treatment of NDs. The primary issue is the low solubility of CUR, so various nanocarriers with biocompatible, non-toxic, cost-effective, and biodegradable properties are used today to increase solubility, enhance penetration rate, reduce dose recurrence, and improve efficacy. It is believed that the phenolic compounds found in turmeric have a neuroprotective effect. Based on numerous pharmacological practices, CUR has been identified as an ideal candidate for various neurological disorders. It can cross the blood-brain barrier (BBB), exhibiting remarkable anti-inflammatory and neuroprotective effects. Use of CUR with nanocarriers can be a potent therapeutic option for NDs.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148230027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating FadD32 as a Target for 7-Substituted Coumarin Derivatives and Other Potential Antimycobacterial Agents.","authors":"Sean Shamido, Jacques Joubert, Samantha Sampson, Afeez I Kareem, Su-Mari du Plessis, Erika Kapp","doi":"10.2174/0115672018429133260523070144","DOIUrl":"https://doi.org/10.2174/0115672018429133260523070144","url":null,"abstract":"<p><strong>Introduction: </strong>The growing burden of drug-resistant mycobacterial infections demands novel therapeutic agents. One strategy for discovering new tuberculosis (TB) drugs is to target essential proteins within validated biosynthetic pathways. FadD32 is a key enzyme in mycolic acid synthesis and is critical for the viability of Mycobacterium tuberculosis (Mtb). Accordingly, identifying potent FadD32 inhibitors represents a promising approach that may help circumvent resistance to existing TB drugs such as isoniazid.</p><p><strong>Methods: </strong>This study employed structure-based drug design using molecular docking to evaluate the binding potential of 7-substituted coumarin derivatives and compounds from the Maybridge database against FadD32. Docking was performed using Hybrid 4.0 software. Top-scoring ligands were screened for antimycobacterial activity against Mycobacterium smegmatis mc²155 using the Alamar Blue assay.</p><p><strong>Results: </strong>All 7-substituted coumarin derivatives exhibited better docking scores than the native ligand of FadD32. Additionally, 14 Maybridge compounds, including diverse scaffolds, also showed favorable docking results. Among them, HTS08202 (a benzimidazole derivative) demonstrated significant activity, inhibiting M. smegmatis mc2155 by 94.12% (±2.34%) and 94.82% (±1.73%) at 50 μM and 25 μM, respectively. CP15, a coumarin-based compound, achieved 82.38% (±3.18%) inhibition at 50 μM. Cytotoxicity assessment revealed that HTS08202 was not toxic at 25 μM, its active concentration.</p><p><strong>Discussion: </strong>The findings highlight the potential of both benzimidazole and coumarin-based derivatives as promising leads for antimycobacterial drug development. The favorable docking scores and biological activity suggest that FadD32 inhibition may be a viable strategy to overcome resistance mechanisms in TB. HTS08202 stands out for its higher inhibition and lower cytotoxicity, and requires further optimization and in vivo evaluation.</p><p><strong>Conclusion: </strong>The identified compounds, especially HTS08202 merit further investigation as potential antimycobacterial agents.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148207414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metal-Organic Frameworks: A Smart Platform for Targeted Drug Delivery in Cancer Therapy.","authors":"Sandip Sonwane, Samiksha Khobragade, Rahul Ingle","doi":"10.2174/0115672018389459251006143041","DOIUrl":"https://doi.org/10.2174/0115672018389459251006143041","url":null,"abstract":"<p><p>The global increase in the incidence of cancer, which is responsible for approximately ten million deaths annually, underscores the urgent need for innovative therapeutic strategies beyond conventional treatments such as surgery, chemotherapy, and radiotherapy. These traditional methods often result in significant adverse effects, necessitating the exploration of targeted approaches to mitigate toxicity and enhance efficacy. Metal-organic frameworks (MOFs) have emerged as promising candidates for advanced cancer treatment, offering unique advantages through their highly porous structures, tunable properties, and multifunctionality. MOFs can enhance drug loading, enable controlled release, and improve targeting specificity, thereby reducing systemic toxicity. Their adaptability allows for combination therapies, theranostic applications, and gene delivery systems. Various metal organic framework (MOF) types, such as Zeolitic Imidazolate Frameworks (ZIFs), Isoreticular- MOFs, and Materials of Institute Lavoisier (MIL), have shown potential in delivering diverse therapeutic agents across different cancer types, including breast, liver, ovarian, and oral cancers. Advancements in synthesis techniques, such as microwave-assisted and electrochemical methods, have improved the efficiency and scalability of MOF production. The integration of MOFs into cancer therapeutics presents a transformative approach to address the limitations of traditional therapies, aiming to improve patient outcomes through targeted and personalized treatment modalities. Future research will focus on enhancing MOF biocompatibility and optimizing their clinical applications, positioning them as cornerstones in the next generation of cancer therapies.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148201895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Innovative Drug Delivery Strategies for Enhanced Treatment of Antimicrobial Resistance.","authors":"Pranay Wal, Ankita Wal, Ajay Kumar, Hanish Singh Jayasingh Chellammal, Pratap Kumar Patra, Manish R Bhise, Dileep Kumar, Sanjana Gupta, Amin Gasmi","doi":"10.2174/0115672018415077251201092315","DOIUrl":"10.2174/0115672018415077251201092315","url":null,"abstract":"<p><strong>Introduction: </strong>Antimicrobial resistance (AMR) presents a major global health threat, driven by the overuse and misuse of antibiotics. Traditional drug delivery systems face significant limitations in effectively addressing this issue, including poor targeting, low bioavailability, and the development of resistance. Nanoparticle-based drug delivery systems (NDDS) have emerged as a novel approach to overcome these limitations and combat resistant bacteria by improving drug delivery and targeting. This review aims to evaluate the mechanisms of AMR and the effectiveness of nanoparticle- based drug delivery systems in combating resistant bacteria.</p><p><strong>Methods: </strong>The methodology employed in this review involved a systematic search of peer-reviewed literature in databases such as PubMed, Google Scholar, Scopus, and Web of Science. The search strategy focused on identifying relevant articles using keywords and phrases such as \"nanoparticle drug delivery systems,\" \"antimicrobial resistance,\" \"nanomedicine,\" \"liposomes,\" \"nanoemulsions,\" and \"polymeric nanoparticles.\" The review included studies evaluating the mechanisms of antimicrobial resistance, the applications of NDDS, and their implications and advancements in combating AMR.</p><p><strong>Results: </strong>Nanoscale drug delivery vehicles and antibacterial nanoparticles have demonstrated significant potential as effective treatments for infections. Nanoparticles, with their small and controllable size, offer unique properties such as enhanced reactivity, a functionalizable structure, and a high surface area-to-volume ratio. NDDS, including liposomes, nanoemulsions, solid lipid nanoparticles, polymeric nanoparticles, and metal nanoparticles, have gained attention due to their ability to enhance drug bioavailability and targeting effectiveness.</p><p><strong>Conclusion: </strong>Nanoparticles present a promising strategy to combat AMR. Their capacity to bypass traditional resistance mechanisms and improve drug delivery underscores their potential in the development of effective antimicrobial therapies. Further research is essential to optimize nanoparticle formulations for clinical translation, ensuring their safety and efficacy in treating resistant bacterial infections. This review highlights the importance of integrating nanotechnology into antimicrobial strategies to address the growing challenge of AMR.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13684973/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148201923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research Progress on Alzheimer's Disease with Classical Traditional Chinese Medicine Formulas.","authors":"Jiarui Zhao, Geng Tian, Ying Qu, Yu Liu, Wenjie Wu, Lina Dai, Guowei Zhang, Fengmao An","doi":"10.2174/0115672018401009251117113526","DOIUrl":"https://doi.org/10.2174/0115672018401009251117113526","url":null,"abstract":"<p><p>Alzheimer's disease (AD) is caused by complex pathological changes and is a problem that cannot be ignored by the global public health system. Its main clinical manifestations include progressive cognitive impairment, mental and psychological changes, and, in advanced stages, paralysis and loss of self-care ability. The economic and psychological burdens imposed on AD patients and their caregivers have been progressively exacerbating, while the annual expenditures on AD treatment by nations worldwide and by the United Nations have demonstrated a consistent upward trend rather than a decline. The treatment of AD remains challenging, with currently limited therapeutic options available. The advantages of the multi-target, multi-component, safe, and low-toxicity characteristics of Traditional Chinese Medicine (TCM) have attracted public attention, providing ideas for the prevention and treatment of AD and for the development of new drugs. In this study, 27 TCM formulas reported to exhibit preventive and therapeutic effects on AD in basic or clinical research were identified and summarized. TCM can intervene in the progression of AD by clearing Aβ deposition, inhibiting Tau phosphorylation, reducing neuroinflammation, mitigating mitochondrial dysfunction and oxidative stress, and regulating gut microbiota. This review aims to provide evidence for further exploring the role and potential mechanisms of TCM in the prevention and treatment of AD, and to offer insights for the development of new anti-AD drugs.</p>","PeriodicalId":94287,"journal":{"name":"Current drug delivery","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148140551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}